Rankings
▼
Calendar
FHTX Q4 2024 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
FHTX
Foghorn Therapeutics Inc.
$330M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
-50.5% YoY
Gross Profit
$3M
100.0% margin
Operating Income
-$24M
-840.5% margin
Net Income
-$20M
-682.9% margin
EPS (Diluted)
$-0.31
QoQ Revenue Growth
-63.4%
Cash Flow
Operating Cash Flow
-$25M
Free Cash Flow
-$25M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$284M
Total Liabilities
$330M
Stockholders' Equity
-$46M
Cash & Equivalents
$55M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$6M
-50.5%
Gross Profit
$3M
$5M
-41.9%
Operating Income
-$24M
-$25M
+5.7%
Net Income
-$20M
-$24M
+19.1%
← FY 2024
All Quarters
Q1 2025 →